Rare cancers account for ~25–30% of all cancer diagnoses and 25% of cancer deaths, representing a substantial burden of disease. However, basic science research, clinical trials and approval of new therapies for rare cancers are lacking. This translates into a worse prognosis for patients with a rare cancer than for those with common cancers. With the number of rare cancers increasing, finding more appropriate solutions for diagnosing, managing and studying rare cancers is essential.
Lynnette Fernandez-Cuesta and Matthieu Foll will be presenting at the upcoming EMBL Cancer Genomics Conference ...
As every year, a unique opportunity to learn about the advances made in the field ...
Lynnette Fernandez-Cuesta was invited discussant in the first ESMO meeting including Rare Cancers. Great initiative ...
Rare Cancer Genomics